NCT02202785View on ClinicalTrials.gov

A Study of MLN0264 in Patients With Pancreatic Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

July 2, 2014

Primary Completion Date

January 15, 2016

Study Completion Date

January 15, 2016

Conditions
Pancreatic Adenocarcinoma
Interventions
DRUG

MLN0264

MLN0264 IV infusion

Trial Locations (16)

Unknown

Aurora

St. Petersburg

Tampa

Boston

Cincinnati

Nashville

San Antonio

Bruges

Leuven

Barcelona

Madrid

Málaga

Seville

London

Manchester

Sutton

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT02202785 - A Study of MLN0264 in Patients With Pancreatic Cancer | Biotech Hunter | Biotech Hunter